Evaluating mental health risks and protective factors in transitional age youth
Multicentre Prospective Interventional Cohort Study Assessing Risk and Protective Factors to Develop Psychopathology in Transitional Age Youth
This study is trying to understand what helps or harms the mental health of young people around 17 years old to improve support for them during this important time in their lives.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 17 Years to 17 Years |
| Sex | All |
| Sponsor | Queen Fabiola Children's University Hospital Academic / other |
| Locations | 4 sites (Brussels and 3 other locations) |
| Trial ID | NCT04333797 on ClinicalTrials.gov |
What this trial studies
This clinical study focuses on transitional age youth, specifically those around 17 years old, to evaluate risk and protective factors that contribute to the development of mental disorders. The study will recruit 300 participants, including inpatients, outpatients, and a control group, and assess them at baseline and again two years later. The aim is to identify clinical characteristics that influence mental health during this critical transition period and to develop a non-stigmatizing approach to improve social inclusion and reduce rejection among youths experiencing psychopathological issues.
Who should consider this trial
Good fit: Ideal candidates for this study are French-speaking youth aged 17 who are either inpatients, outpatients, or part of the general population.
Not a fit: Patients with medium intellectual disabilities or severe somatic diseases that affect their vital prognosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved mental health care strategies for transitional age youth, enhancing their social inclusion and overall well-being.
How similar studies have performed: Other studies have shown success in addressing mental health transitions in youth, but this specific approach focusing on dimensional characteristics is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * French-speaking and French-understanding * Subjects who accepted to participated to the study (signature of informed consent/assent document from subjects and parents or legal holder of parental authority) * Specific criteria for patients: inpatients and out-patients * Specific criteria for control group: youth from general population or placed in residential centres Exclusion Criteria: * Impossibility to answer to the assessment tools * Medium intellectual disability (homogenous IQ \< 75) * Presence of a grave somatic disease (cancer, cardiac failure, renal failure, central nervous system disorder), that is progressive or that affects the vital prognosis in the short term * Active participation to another study
Where this trial is running
Brussels and 3 other locations
- Brugmann University Hospital — Brussels, Belgium (Recruiting)
- Hôpital Universitaire Des Enfants Reine Fabiola — Brussels, Belgium (Recruiting)
- Service santé mentale à l'ULB — Brussels, Belgium (Recruiting)
- Erasme University Hospital — Brussels, Belgium (Recruiting)
Study contacts
- Principal investigator: Véronique Delvenne, MD, PhD — Queen Fabiola Children's University Hospital
- Study coordinator: Véronique Delvenne, MD, PhD
- Email: veronique.delvenne@huderf.be
- Phone: +32 2 477 21 17
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.